Gene therapy clinical trials worldwide to 2017: An update

To date, almost 2600 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. Our database brings together global information on gene therapy clinical activity from trial databases, official agency sources, published literature, conference presentations and posters kindly provided to us by individual investigators or trial sponsors. This review presents our analysis of clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of our November 2017 update, we have entries on 2597 trials undertaken in 38 countries. We have analysed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and the genes that have been transferred. Details of the analyses presented, and our searchable database are available via The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. We also provide an overview of the progress being made in gene therapy clinical trials around the world, and discuss key trends since the previous review, namely the use of chimeric antigen receptor T cells for the treatment of cancer and advancements in genome editing technologies, which have the potential to transform the field moving forward.

[1]  Michel Sadelain CAR therapy: the CD19 paradigm. , 2015, The Journal of clinical investigation.

[2]  Matthew J. Moscou,et al.  A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.

[3]  J. Bennett Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  M. Gonçalves,et al.  Engineered Viruses as Genome Editing Devices , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Steven M. Weisberg,et al.  A CRISPR New World: Attitudes in the Public toward Innovations in Human Genetic Modification , 2017, Front. Public Health.

[6]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[7]  Daniele Merico,et al.  Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism , 2017, Nature Medicine.

[8]  S. Russell,et al.  Oncolytic Virotherapy: A Contest between Apples and Oranges. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[10]  P. Ortinski,et al.  Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing , 2017, Molecular therapy. Methods & clinical development.

[11]  B. Smart Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome , 2011, Pediatrics.

[12]  John K. Hall,et al.  Progress and prospects of gene therapy clinical trials for the muscular dystrophies. , 2016, Human molecular genetics.

[13]  L. Notarangelo,et al.  Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency , 2016, Science Translational Medicine.

[14]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[15]  N. Sardesai,et al.  Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy , 2017, Clinical Cancer Research.

[16]  Donald Kennedy,et al.  Breakthrough of the Year , 2007, Science.

[17]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[18]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[19]  A. Miccio,et al.  Gene Therapy for β-Hemoglobinopathies. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  S. Ludwig,et al.  Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy , 2017, Biological chemistry.

[21]  T. Flotte,et al.  Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency , 2017 .

[22]  E. Bender Gene therapy: Industrial strength , 2016, Nature.

[23]  Dennis Normile iPS cell therapy reported safe. , 2017, Science.

[24]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[25]  W. Baehr,et al.  RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations , 2014, Front. Mol. Neurosci..

[26]  David Cyranoski,et al.  CRISPR gene-editing tested in a person for the first time , 2016, Nature.

[27]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[28]  Shinya Yamanaka,et al.  Induced pluripotent stem cell technology: a decade of progress , 2016, Nature Reviews Drug Discovery.

[29]  A. Sood,et al.  RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. , 2016, Cancer treatment reviews.

[30]  J. Couzin Method to Silence Genes Earns Loud Praise , 2006, Science.

[31]  E. Callaway Doubts raised about CRISPR gene-editing study in human embryos , 2017 .

[32]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Inder M. Verma,et al.  Gene therapy: trials and tribulations , 2000, Nature Reviews Genetics.

[34]  Wenbo Zhou,et al.  Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells , 2009, Stem cells.

[35]  Ying Sun,et al.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes , 2015, Protein & Cell.

[36]  J. Grieger,et al.  Manufacturing of recombinant adeno-associated viral vectors for clinical trials , 2016, Molecular therapy. Methods & clinical development.

[37]  J. Chamberlain,et al.  Progress toward Gene Therapy for Duchenne Muscular Dystrophy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[39]  H. Ertl,et al.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. , 2013, Blood.

[40]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[41]  Michael Rothe,et al.  Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.

[42]  Yong Huang,et al.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice , 2014, Nature.

[43]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[44]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[45]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[46]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[47]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[48]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[49]  Jianhui Gong,et al.  Correction of a pathogenic gene mutation in human embryos , 2018, Yearbook of Paediatric Endocrinology.

[50]  S. Ylä-Herttuala ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Sara Reardon,et al.  Chinese scientists genetically modify human embryos , 2015, Nature.

[52]  Anirvan Ghosh,et al.  Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes , 2017, Nature Biotechnology.

[53]  Sara Reardon,et al.  Leukaemia success heralds wave of gene-editing therapies , 2015, Nature.

[54]  N. Svrzikapa,et al.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.

[55]  M. Boulton,et al.  Systemic Injection of RPE65-Programmed Bone Marrow-Derived Cells Prevents Progression of Chronic Retinal Degeneration , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  A. Biffi Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  R. Grossman,et al.  HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.

[58]  J. Davies,et al.  Gene Therapy in a Patient with Sickle Cell Disease. , 2017, The New England journal of medicine.

[59]  V. Ricotti,et al.  Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study , 2014, The Lancet Neurology.

[60]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[61]  S Chandrasegaran,et al.  Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Yong Wang,et al.  Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9 , 2017, Science.

[63]  Xiuyan Wang,et al.  Clinical manufacturing of CAR T cells: foundation of a promising therapy , 2016, Molecular therapy oncolytics.

[64]  M. Nirenberg Will society be prepared? , 1967, Science.

[65]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[66]  Jean Bennett,et al.  Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.

[67]  Lei Zhang,et al.  Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. , 2002, Biochimica et biophysica acta.

[68]  J. Couzin Nobel Prize in Physiology or Medicine. Method to silence genes earns loud praise. , 2006, Science.

[69]  Michael Dallas,et al.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial , 2015, The Lancet.

[70]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[71]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[72]  Patrick Hong,et al.  Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing , 2016, Molecular therapy. Methods & clinical development.

[73]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[74]  F. Demichelis,et al.  Hit and go CAS9 delivered through a lentiviral based self-limiting circuit , 2017, Nature Communications.

[75]  F. Bushman,et al.  Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. , 2017, Blood.

[76]  Kathryn L. Parsley,et al.  Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.

[77]  R. Calne,et al.  Gene therapy for hemophilia A. , 2006, Discovery medicine.

[78]  Ian J Constable,et al.  Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial , 2015, The Lancet.

[79]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[80]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2007—an update , 2007, The journal of gene medicine.

[81]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[82]  J. Wixon,et al.  Gene therapy clinical trials worldwide 1989–2004—an overview , 2004, The journal of gene medicine.

[83]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[84]  Helen E Heslop,et al.  CAR-T Cell Therapy for Lymphoma. , 2016, Annual review of medicine.

[85]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[86]  Michel Sadelain,et al.  Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  Y. Doyon,et al.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.

[88]  E. Wagner,et al.  Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). , 2015, Chemical reviews.

[89]  Roland W Herzog,et al.  Evading the immune response upon in vivo gene therapy with viral vectors. , 2009, Current opinion in molecular therapeutics.

[90]  S. Hughes,et al.  Altering the Genome by Homologous Recombination , 2010 .

[91]  J. Rasko,et al.  Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant , 2017, The New England journal of medicine.

[92]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[93]  Irene Georgakoudi,et al.  Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles , 2016, Proceedings of the National Academy of Sciences.

[94]  K. Makino,et al.  Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product , 1987, Journal of bacteriology.

[95]  Sara Reardon,et al.  Japan stem-cell trial stirs envy , 2014, Nature.

[96]  K. Lundstrom Special Issue: Gene Therapy with Emphasis on RNA Interference , 2015, Viruses.

[97]  Frederic D Bushman,et al.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.

[98]  D J Segal,et al.  Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[99]  S. Borwornpinyo,et al.  Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene , 2016, Human gene therapy.

[100]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[101]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[102]  David A. Williams,et al.  Evolving Gene Therapy in Primary Immunodeficiency. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  David A. Williams,et al.  Hematopoietic Stem‐Cell Gene Therapy for Cerebral Adrenoleukodystrophy , 2017, The New England journal of medicine.

[104]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[105]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[106]  Robert Lanza,et al.  Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.

[107]  P. Rosenfeld,et al.  Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies , 2015, The Lancet.

[108]  Kathryn L. Parsley,et al.  Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.

[109]  S. Orkin,et al.  Paying for future success in gene therapy , 2016, Science.

[110]  A. Higuchi,et al.  Stem Cell Therapies for Reversing Vision Loss. , 2017, Trends in biotechnology.

[111]  Xianquan Zhang,et al.  Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[112]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[113]  P. Cullis,et al.  Lipid Nanoparticle Systems for Enabling Gene Therapies. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[114]  M. Roncarolo,et al.  Ten years of gene therapy for primary immune deficiencies. , 2009, Hematology. American Society of Hematology. Education Program.

[115]  Kathleen A. Marshall,et al.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial , 2009, The Lancet.

[116]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[117]  Giovanni Staurenghi,et al.  Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. , 2017, The New England journal of medicine.

[118]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[119]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[120]  I. Constable,et al.  Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration , 2016, EBioMedicine.

[121]  Claudio Mussolino,et al.  Refining strategies to translate genome editing to the clinic , 2017, Nature Medicine.

[122]  Seppo Ylä-Herttuala,et al.  Cardiovascular Gene Therapy: Past, Present, and Future. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[123]  E. Lanphier,et al.  Don’t edit the human germ line , 2015, Nature.

[124]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[125]  Michael L Kaufman,et al.  Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  K. Flanigan,et al.  Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene , 2014, Molecular therapy. Nucleic acids.

[127]  K. Garber RIKEN suspends first clinical trial involving induced pluripotent stem cells , 2015, Nature Biotechnology.

[128]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[129]  T. Flotte,et al.  5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[130]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[131]  A. Aartsma-Rus FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. , 2017, Nucleic acid therapeutics.

[132]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[133]  Jennifer A. Doudna,et al.  A prudent path forward for genomic engineering and germline gene modification , 2015, Science.

[134]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[135]  Monya Baker,et al.  Gene-editing nucleases , 2011, Nature Methods.

[136]  D. Russell,et al.  Human gene targeting by viral vectors , 1998, Nature Genetics.

[137]  L. Naldini,et al.  Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products , 2017, EMBO molecular medicine.

[138]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[139]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[140]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[141]  X. Anguela,et al.  Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a , 2017 .

[142]  Philippe Horvath,et al.  A decade of discovery: CRISPR functions and applications , 2017, Nature Microbiology.

[143]  Sara Reardon Gene-editing record smashed in pigs , 2015, Nature.

[144]  Kyung-Chul Choi,et al.  Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy , 2016, Oncotarget.

[145]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[146]  Steve Cunningham,et al.  Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .

[147]  I. Alexander,et al.  Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects , 2017, Journal of Inherited Metabolic Disease.

[148]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[149]  Henry Klassen,et al.  Stem cells in clinical trials for treatment of retinal degeneration , 2016, Expert opinion on biological therapy.

[150]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.